上海醫藥(601607.SH):不超11.5億元取得T3011(瘤內注射)項目在大中華地區商業化的獨家權益
格隆匯 8 月 6日丨上海醫藥(601607.SH)公佈,2020年8月6日,公司與深圳市亦諾微醫藥科技有限公司(“亦諾微”)簽訂《授權許可協議》,將出資不超過人民幣11.5億元取得T3011(瘤內注射)項目在大中華地區(中國大陸、香港、澳門以及台灣)商業化的獨家權益。
T3011是新一代的溶瘤HSV病毒產品,採用了專有的病毒骨架並且插入了獨特的細胞因子組合(IL-12和PD-1抗體),在兼顧安全性的同時提高了病毒的殺傷力,進一步強化了免疫協同抗腫瘤作用。
溶瘤病毒是一種病毒特異性感染並殺傷腫瘤細胞的新型腫瘤療法,通過直接裂解腫瘤細胞激發機體系統性的抗腫瘤免疫反應。從作用機理來看,溶瘤病毒具有與化療、放療、靶向藥物、免疫治療等多種腫瘤療法協同聯用增效的潛力,並且可作為一種基因遞送的載體工具。
T3011(瘤內注射)項目的國內IND申請已於2019年8月獲批,正在上海復旦大學腫瘤醫院等機構開展針對實體瘤適應症的I期臨牀試驗,目前已入組患者。同時,T3011(瘤內注射)項目的美國IND已於2020年5月獲得美國FDA批准。
目前,全球已經上市的溶瘤病毒產品包括美國Amgen公司的T-VEC和上海三維生物技術有限公司的安柯瑞。根據Evaluate Pharma數據庫,2019年溶瘤病毒產品全球銷售額為0.68億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.